Patents by Inventor Esther Helen Rose

Esther Helen Rose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanoma therapy
    Patent number: 7482014
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: January 27, 2009
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Melanoma therapy
    Patent number: 6923966
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: August 2, 2005
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Renal cell carcinoma treatment
    Patent number: 6605273
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.
    Type: Grant
    Filed: July 9, 2001
    Date of Patent: August 12, 2003
    Assignee: Schering Corporation
    Inventors: Mary Ellen Ryback, Esther Helen Rose
  • CML Therapy
    Patent number: 6362162
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having CML to achieve at least a partial cytogenetic response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of Ara-C are disclosed.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: March 26, 2002
    Assignee: Schering Corporation
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Renal cell carcinoma treatment
    Publication number: 20010053548
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., pegylated interferon alpha-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.
    Type: Application
    Filed: July 9, 2001
    Publication date: December 20, 2001
    Inventors: Mary Ellen Rybak, Esther Helen Rose
  • Melanoma therapy
    Publication number: 20010038833
    Abstract: Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
    Type: Application
    Filed: July 12, 2001
    Publication date: November 8, 2001
    Inventors: Mary Ellen Rybak, Esther Helen Rose